NYSE:LLY
NYSE:LLYPharmaceuticals

Eli Lilly (NYSE:LLY) Advances Orforglipron GLP-1 Therapy To Phase 3 With Positive Results

Eli Lilly (NYSE:LLY) recently announced positive Phase 3 trial results for orforglipron, the first oral small molecule GLP-1 receptor agonist showing superior A1C reduction in type 2 diabetes patients, which aligns with a 7% share price increase over the last month. This, along with new offerings for Zepbound and strategic collaborations, potentially supported the company's stock performance. While the broader market showed a flat trajectory, the company's developments likely added weight to...